Compare DY & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DY | HALO |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.8B |
| IPO Year | 1995 | 2001 |
| Metric | DY | HALO |
|---|---|---|
| Price | $410.31 | $70.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $425.30 | $78.18 |
| AVG Volume (30 Days) | 362.6K | ★ 1.2M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.71 | N/A |
| EPS | ★ 9.56 | 2.56 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $30.96 | $28.24 |
| Revenue Next Year | $9.49 | $12.56 |
| P/E Ratio | $41.85 | ★ $27.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $150.29 | $47.50 |
| 52 Week High | $445.53 | $82.22 |
| Indicator | DY | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 67.07 | 61.36 |
| Support Level | $331.58 | $67.94 |
| Resistance Level | $445.53 | $71.53 |
| Average True Range (ATR) | 13.33 | 1.87 |
| MACD | 6.32 | 0.78 |
| Stochastic Oscillator | 96.15 | 94.03 |
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.